Becton looks to enter oncology screening market:
This article was originally published in Clinica
Becton Dickinson has signaled its intention to move into oncology screening, staging and pharmacogenomics in a five-year strategic alliance with Millennium Predictive Medicine, a subsidiary of Millennium Pharmaceuticals. Becton Dickinson will pay $15 million upfront and a $3 million licensing fee, with overall investment totalling $70 million. At the same time Becton has also purchased a small privately-owned company which has interests in cancer diagnosis and management. Biometric Imaging has an FDA-approved diagnostic device and four tests, including cancer patient monitoring.